Aurobindo Pharma has announced that its step-down subsidiary, CuraTeQ Biologics B.V., has incorporated a new wholly-owned subsidiary in Malta. The newly established entity is named CuraTeQ Biologics (Malta) Limited. This strategic move aims to expand the company’s pharmaceutical products business in Malta. The incorporation, completed on September 26, 2025, involved an initial share capital subscription of EUR 1200.
Malta Subsidiary Launch
Aurobindo Pharma, through its subsidiary CuraTeQ Biologics B.V., has expanded its global presence with the incorporation of CuraTeQ Biologics (Malta) Limited in Malta. This new entity, a wholly-owned subsidiary, was officially incorporated on September 26, 2025.
Strategic Rationale
The primary objective behind establishing CuraTeQ Biologics (Malta) Limited is to broaden Aurobindo Pharma’s pharmaceutical business operations within Malta. CuraTeQ Biologics B.V., the Netherlands, remains a key part of the Aurobindo structure.
Financial Details of Incorporation
The incorporation involved an initial subscription to the share capital amounting to EUR 1200. This capital is divided into 1200 shares, each with a nominal value of EUR 1.00.
Source: BSE
